Viral Genetics to Present at Rodman & Renshaw Healthcare Conference and The PIPEs Conference
Posted on: Thursday, 2 November 2006, 12:01 CST
AZUSA, Calif, Nov. 2 /PRNewswire-FirstCall/ -- Viral Genetics, Inc. (BULLETIN BOARD: VRAL) will present at the following two investment community conferences:
Rodman & Renshaw 8th Annual Healthcare Conference Wednesday, November 8, 2006 at 9:30 a.m. EST The New York Palace Hotel in the Holmes II room The PIPEs Conference 2006 Wednesday, November 8, 2006 at 1:30 p.m., 2 p.m., 2:30 p.m. EST The Waldorf-Astoria, New York City
A live web cast of the Rodman & Renshaw presentation will be available in the Investors section of Viral Genetics' web site at http://www.viralgenetics.com/. The web cast will be archived and accessible for 90 days.
About Viral Genetics
Viral Genetics, Inc. is a biotechnology company that discovers and develops immune-based therapies for HIV and AIDS using its thymus nuclear protein compound. This compound may have other potential applications for other infectious, autoimmune, and immunological deficiency diseases that the company intends to study in the future. Viral Genetics believes that VGV-1 represents a significant and unique approach to treating HIV due to the apparently novel mechanism, low toxicity profile, simple dosing regimen, and short-course of treatment. Online at http://www.viralgenetics.com/
For additional information, please contact Kirsten Ayars at 805-452-7909. For investor inquiries, please contact Evan Pondel at 310-279-5973.
This news release contains forward-looking statements that involve risks and uncertainties associated with clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports filed with the SEC. VGV-1 is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Viral Genetics believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of VGV-1 in the treatment of any disease or health condition and the development of studies and strategies leading to commercialization of VGV-1 in the United States. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.
Viral Genetics, Inc.
CONTACT: Kirsten Ayars, +1-805-452-7909, or Investors, Evan Pondel,+1-310-279-5973, both for Viral Genetics, Inc.
Web site: http://www.viralgenetics.com/
Company News On-Call: http://www.prnewswire.com/comp/905553.html
Source: PRNewswire-FirstCall
Related Articles
- Viral Genetics' AIDS Study Results to Be Presented at Institute of Human Virology's 2006 International Meeting
- Viral Genetics Adds Two Harvard Specialists to Scientific Advisory Board
- Viral Genetics to Present at EdgeWater Investment Conference
- Viral Genetics to Exhibit at ICAAC
- Viral Genetics Appoints Dr. Eric S. Rosenberg Chairman of Scientific Advisory Board
- Viral Genetics' AIDS Study Yields Encouraging Results
- Viral Genetics Announces Results of South African Study of VGV-1
- Viral Genetics Updates on Release of Results of Phase III Study of VGV-1 for the Treatment of HIV Infection
- Service Providers Can Look Forward to Busy Year
 |
 |
User Comments (0)
RSS Feeds